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Glucose metabolism causes activation of the yeast plasma-
membrane H+-ATPase. The molecular mechanism of this regu-
lation is not known, but it is probably mediated by phosphoryla-
tion of the enzyme. The involvement in this process of several
kinases has been suggested but their actual role has not been
proved. The physiological role of a calmodulin-dependent protein
kinase in glucose-induced activation was investigated by studying
the effect of specific calmodulin antagonists on the glucose-
induced ATPase kinetic changes in wild-type and two mutant
strains affected in the glucose regulation of the enzyme. Pre-
incubation of the cells with calmidazolium or compound 48}80
impeded the increase in ATPase activity by reducing the V
max
of
the enzyme without modifying the apparent affinity for ATP in
the three strains. In one mutant, pma1-T912A, the putative
calmodulin-dependent protein kinase-phosphorylatable Thr-912
was eliminated, and in the other, pma1-P536L, H+-ATPase was
INTRODUCTION
The plasma-membrane H+-ATPase (Pma1) of yeast cells belongs
to the family of P-type ATPases [1,2]. It hydrolyses ATP and
transports protons from the cytosol to the extracellular medium.
The electrochemical gradient it creates is the driving force for
nutrient uptake. The enzyme also plays an essential role in the
maintenance of intracellular pH (for reviews see [3–7]). The
crucial physiological role of the ATPase requires its strict
regulation. It is known that H+-ATPase activity is regulated in
response to growth conditions [8–11], and glucose is the external
signal that has been most extensively investigated. It has a dual
role in regulating both the expression and catalytic activity of the
plasma-membrane H+-ATPase. On the one hand, glucose metab-
olism increases ATPase gene (PMA1) transcription [12] and, on
the other, it induces a modification of the enzyme’s kinetic
properties [8], resulting in an overall stimulation of ATPase
activity. The molecular mechanism of glucose-induced activation
is not known, but it is based on the elimination of an inhibitory
interaction of the C-terminus with the active site of the enzyme
[13,14], probably mediated by Ser}Thr phosphorylation of the
enzyme [15]. In fact, several C-terminal amino acids important in
H+-ATPase regulation have been identified using site-directed
mutagenesis [14,16]. The residues that are essential for glucose
activation define the potential phosphorylation sites for casein
kinase II and calmodulin-dependent protein kinase II [17] which
are necessary for the glucose-induced K
m
and V
max
changes
respectively [14,16]. The physiological role of casein kinase II in
Abbreviations used: DSS, suberic acid bis-(N-hydroxysuccinimide ester) ; P536L, mutant of yeast plasma-membrane H+-ATPase with Leu substituted
for Pro-536; P890X, mutant of yeast plasma-membrane H+-ATPase with an opal stop codon substituted for Pro-890; T912A, mutant of yeast plasma-
membrane H+-ATPase with Ala substituted for Thr-912.
* Present address : Departamento de Bioenerge! tica, Instituto de Fisiologı!a Celular, Universidad Nacional Auto! noma de Me! xico, Apartado Postal 70-
243, 04510 Me! xico, D.F.
 To whom correspondence should be addressed.
constitutively activated, suggesting that the antagonistic effect
was not mediated by a calmodulin-dependent protein kinase and
not related to glucose regulation. This was corroborated when
the in itro effect of the calmodulin antagonists on H+-ATPase
activity was tested. Purified plasma membranes from glucose-
starved or glucose-fermenting cells from both pma1-P890X,
another constitutively activated ATPase mutant, and wild-type
strains were preincubated with calmidazolium or melittin. In all
cases, ATP hydrolysis was inhibited with an IC
&!
of E 1 lM.
This inhibition was reversed by calmodulin. Analysis of the
calmodulin-binding protein pattern in the plasma-membrane
fraction eliminates ATPase as the calmodulin target protein. We
conclude that H+-ATPase inhibition by calmodulin antagonists
is mediated by an as yet unidentified calmodulin-dependent
membrane protein.
glucose-induced activation of the H+-ATPase is not known,
although there is evidence that Ser-899, the phosphorylatable
residue in the consensus site for this kinase, could be phos-
phorylated during glucose activation of the enzyme [16]. In-
volvement of a calmodulin-dependent protein kinase in glucose
activation is less clear, since there is no evidence that Thr-912, the
phosphorylatable residue in the ATPase consensus sequence for
calmodulin-dependent protein kinase II, is phosphorylated [16].
Nevertheless, results obtained in io using several kinase
inhibitors [18] indicate that glucose-induced activation of the
enzyme could be mediated by a calmodulin-dependent protein
kinase. To unravel the role of calmodulin-dependent protein
kinase in glucose activation of H+-ATPase, we studied the effect
of calmodulin antagonists on the glucose-induced activation of
glucose-regulation mutants. We describe potent inhibitory effects
of these compounds that affect the V
max
of the enzyme, and we
show, in io and in itro, that these effects are not related to
glucose regulation of the enzyme. The inhibition affects the basal
activity of the enzyme and can be reversed by calmodulin,
suggesting modulation of the H+-ATPase activity through a
calmodulin-binding protein.
MATERIALS AND METHODS
Yeast strain and growth medium
The strain used was Saccharomyces cereisiae RS-72 transformed
with pSB32, an autonomous and centromeric plasmid with the
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LEU2 gene for transformant selection [19], containing a 5 kb
HindIII fragment that includes either the wild-type or the selected
mutant allele of the pma1 gene. RS-72 is a derivative of BWG1-
7A (MATa, ade1-100, his4-519, leu2-3,112 and ura3-52) [20] in
which the wild-type promoter of PMA1 has been replaced by the
galactokinase gene (gal1) promoter [21]. Cells were grown in
synthetic medium containing 2% glucose or galactose, 0±7%
yeast nitrogen base without amino acids (Difco), 0±2 mM adenine
and 0±4 mM histidine.
Chemicals
Calmidazolium, compound 48}80, melittin, calmodulin and
suberic acid bis-(N-hydroxysuccinimide ester) (DSS) were
obtained from Sigma Chemical Co. "#&I-calmodulin was from
DuPont. All other chemicals used in this work were of analytical
grade.
Expression of mutant ATPases
Mutants were grown to a final A
''!
of 3 (about 10 mg fresh
weight}ml) in galactose medium, in which both the wild-type
(chromosomal) and mutant (plasmid) ATPases are expressed. To
express the mutant enzyme only, the galactose-grown cells were
diluted 100-fold in glucose medium and harvested after 24 h. In
these conditions, cultures expressing active ATPase reach an A
''!
of about 1±5 [21,22].
ATPase activation, homogenization and membrane preparation
conditions
Yeast cells were harvested by centrifugation, washed twice with
deionized water and resuspended at 70 mg fresh weight}ml in
water to eliminate glucose activation [8]. For experiments with
inhibitors, small aliquots of the compound dissolved in methanol
were added to the cell suspension and the final methanol
concentration was kept constant at 2% (v}v). The results of
control experiments with 0 or 2% methanol were identical. After
30 min incubation at 30 °C, 5 ml samples were taken (glucose-
starved cells), frozen in liquid nitrogen and stored at ®70 °C
until use. Then 2% glucose was added to the rest of the
suspension for glucose activation. Samples of volume 5 ml were
taken after 8 min and frozen as above. Homogenization and
membrane preparation were as previously described [8].
ATPase activity
ATP hydrolysis was assayed with 2 mM ATP at 30 °C and
pH 6±5, unless otherwise specified, in buffer containing 5 mM
NaN
$
to inhibit mitochondrial ATPase, 0±2 mM ammonium
molybdate to inhibit acid phosphatase and 50 mM potassium
nitrate to inhibit vacuolar ATPase. Residual activity represented
specific ATP hydrolysis by the plasma-membrane H+-ATPase, as
it was more than 90% inhibited by 1 mM diethylstilboestrol [23].
To measure the effect of inhibitors on ATPase activity, the
assay buffer contained 0±1 mM CaCl
#
, and all enzyme assays
were performed at a protein concentration of 20 lg}ml unless
otherwise stated. Before initiating the reaction by ATP addition,
the plasma membranes were preincubated with the drug for
5 min in the assay medium, followed by an additional 5 min in
the absence or presence of calmodulin when indicated.
Calmidazolium and compound 48}80 were dissolved in meth-
anol. The final methanol concentration in the assay medium
including the controls was always ! 4% (v}v).
125I-Calmodulin cross-link
"#&I-Calmodulin cross-linkage to plasma-membrane proteins was
performed essentially as described [24]. Membrane fractions
(80 lg of protein) were incubated at 37 °C for 30 min in 100 ll of
50 mM Hepes (sodium salt), pH 7±4, containing 1 mM PMSF,
200 lM CaCl
#
or 2 mM EGTA and 100 nCi of "#&I-calmodulin
(90–110 lCi}lg). Samples were subsequently incubated at 0 °C
for 20 min in the presence of a 3 mM concentration of the cross-
linking agent DSS, and thereafter 250 mM glycine was added to
terminate the reaction. Controls were performed with an excess
(1±2 lM) of unlabelled calmodulin to displace the bound "#&I-
calmodulin before addition to DSS. The samples were pre-
cipitated with 15% (w}v) trichloroacetic acid, centrifuged in a
microcentrifuge and the pellets processed for SDS}PAGE and
autoradiography or Western blotting as described below.
Protein analysis
Protein concentration was measured by the Bradford method
[25], using the Bio-Rad protein assay reagent and bovine IgG as
standard. SDS}PAGE was performed as described [26] in 6%
polyacrylamide gels. Samples were prepared as described [27].
The gels were stained with Coomassie Brilliant Blue R-250, and
vacuum dried at 70 °C on Whatman 3MM filter paper. Auto-
radiographs were obtained using an intensifying screen by
exposure of X-ray-sensitive Hyperfilm-MP (Amersham) at
®20 °C. For Western-blot analysis, proteins were transferred to
Immobilon P membranes (Millipore). Transfer buffer was 50 mM
Tris}38 mM glycine}20% methanol. Transfer was carried out
for 1±5 h at a constant current of 2 mA}cm#. Immunodetection
of ATPase was carried out using monoclonal antibody AT1-1-
A4}1-A6 [28] diluted 1:6000. A second antibody coupled to
alkaline phosphatase (Bio-Rad) was used as described [29].
RESULTS
Effect of calmodulin antagonists on glucose-induced activation of
H+-ATPase
One way to study the physiological role of the calmodulin-
dependent protein kinase in plasma-membrane H+-ATPase ac-
tivation by glucose is selective inhibition of its activity using
specific calmodulin antagonists. Calmidazolium and compound
48}80 were selected on the basis of their wide use as calmodulin-
specific inhibitors [30–32]. Table 1 shows that the in io
activation of the plasma-membrane H+-ATPase by glucose was
progressively inhibited when cells were treated with increasing
inhibitor concentrations before addition of glucose. Activation
by glucose was virtually abolished at 400 lM calmidazolium or
400 lg}ml compound 48}80. These inhibitor concentrations were
used in subsequent in io experiments. The inhibitor con-
centration is higher than that used for specific enzyme inhibition
in itro, as the cationic nature of these inhibitors limits their entry
into the phospholipid phase of the membrane [33]. The results
point to involvement of calmodulin-dependent protein kinase in
glucose-induced activation of the H+-ATPase and are consistent
with previous results [18].
Effect of calmodulin antagonists on the glucose-induced changes
in H+-ATPase kinetic parameters
Glucose treatment of wild-type cells induces important changes
in the kinetic characteristics of plasma-membrane ATPase.
Among them are a decrease in the K
m
for ATP and an increase
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Table 1 Inhibition of glucose-induced H+-ATPase activation by calmodulin
antagonists
Cells were cultured, collected and treated with various concentrations of calmidazolium or
compound 48/80 and glucose as outlined in the Materials and methods section. The ATPase
assay was carried out with 2 mM ATP at pH 6±5 in purified plasma membranes as described
in the Materials and methods section. ATPase activity of glucose-starved cells was
0±12 lmol/min per mg. The concentration for calmidazolium was in lM and for compound
48/80 in lg/ml. Results shown correspond to the mean of two experiments differing by less
than 10%.
Antagonist
ATPase activity of glucose-fermenting cells
(lmol/min per mg)
concentration ­Calmidazolium ­Compound 48/80
0 1±87 1±90
25 1±57 1±64
50 1±05 1±12
100 0±84 0±92
150 0±62 0±56
200 0±52 0±50
400 0±17 0±24
in V
max
[8]. Some pma1 mutants that are affected in their glucose
regulation have been described [13,14,16] in which these glucose-
induced kinetic parameters are altered in different ways. To
specify further the extent to which the calmodulin antagonists
affect glucose-induced activation of the ATPase, we measured
their effect on the activity and kinetic properties of the enzyme in
two such mutants. In one, pma1-T912A, elimination of the
putative calmodulin-dependent protein kinase-phosphorylatable
Thr-912, localized in the regulatory domain, results in an enzyme
that is defective in the V
max
increase but which exhibits the typical
glucose-triggered K
m
decrease. In the other mutant, pma1-P536L,
the replacement of Pro-536 with leucine in the proposed ATP-
binding domain probably eliminates the inhibitory interaction of
the C-terminus with that domain resulting in a constitutively
activated ATPase (K
m
and V
max
), even in the absence of glucose
metabolism. Preincubation with calmidazolium or compound
48}80 abolishes glucose activation in wild-type and mutant
enzymes (Table 2). The effect of calmidazolium on the kinetic
parameter changes induced by glucose is shown in Table 3. The
K
m
decrease is produced in glucose-fermenting cells of the wild-
type and pma1-T912A strains, whether they are treated with
Table 2 Effect of calmodulin antagonists on glucose-induced activation of
H+-ATPase mutants affected in their glucose regulation
Cells were cultured, collected and treated with glucose as described in the Materials and
methods section. Cells treated with inhibitors were preincubated with 400 lM calmidazolium
or 400 lg/ml compound 48/80 before the addition of glucose. The ATPase assay was carried
out with 2 mM ATP at pH 6±5 in purified plasma membranes, as described in the Materials
and methods section. GS, glucose-starved cells ; GF, glucose-fermenting cells. The results
shown are means of two experiments differing by less than 10%.
ATPase activity (lmol/min per mg)
Mutation in the
ATPase allele expressed GS GF
GF­
calmidazolium
GF­
compound 48/80
None (wild-type) 0±07 1±41 0±08 0±12
T912A 0±04 0±18 0±05 0±08
P536L 1±76 1±95 0±28 0±24
Table 3 Effect of calmidazolium on the kinetic properties of mutant
ATPases affected in their glucose regulation
ATPase activity was assayed at pH 6±5 with ATP concentrations from 0±8 to 6 mM. The
apparent Km (mM) and Vmax (lmol/min per mg of protein) were extrapolated from double-
reciprocal plots fitted by using a standard linear regression program (P ¯ 0±97–0±99). Similar
values (within 10%) were obtained with two different independently isolated purified plasma-
membrane preparations. GS, glucose-starved cells ; GF, glucose-fermenting cells ; GFC,
calmidazolium-treated glucose-fermenting cells. Cells were grown, collected and treated with
calmidazolium and glucose as described in the Materials and methods section.
Mutation in the
ATPase allele
Km Vmax
expressed GS GF GFC GS GF GFC
None (wild-type) 4±0 1±4 1±3 0±3 3±0 0±1
T912A 4±0 1±4 1±2 0±1 0±3 0±1
P536L 1±3 1±0 1±1 2±8 3±0 0±4
calmidazolium or not. This glucose-induced decrease in K
m
is not
produced in the pma1-P536L mutant, as it was already low [16],
nor is this behaviour modified by calmidazolium. On the other
hand, the glucose-induced V
max
increase is not produced in the
wild-type strain, nor is the small increase in pma1-T912A
observed. Even the glucose-independent constitutive effect of the
P536L mutation is abolished in the presence of calmidazolium.
The results indicate that the calmodulin antagonists affect the
V
max
of the enzyme, whereas the K
m
remains unaltered. This effect
is unrelated to glucose activation since the calmodulin antagonists
inhibit a mutant, pma1-P536L, the ATPase of which is completely
independent of glucose metabolism. The results also suggest that
the inhibitory effect of calmidazolium and compound 48}80 is
not mediated by elimination of calmodulin-dependent phos-
phorylation of the ATPase, since these antagonists inhibit a
mutant, pma1-T912A, in which the putative phosphorylatable
residue has been eliminated.
Effect of calmodulin and calmidazolium on in vitro H+-ATPase
activity
If a calmodulin-dependent protein kinase is not involved in the
inhibition of the ATPase activity caused by calmodulin
antagonists, it is feasible that another calmodulin-specific re-
ceptor system could be implicated. Several enzymes are known
that possess an autoinhibitory domain that is removed on binding
of calmodulin to the enzyme itself [34], thereby activating the
enzyme. The basal activity of these enzymes is stimulated in itro
when the enzyme assay is performed in the presence of
calmodulin. This calmodulin-stimulated activity can also be
inhibited in itro by calmodulin antagonists. We have considered
these possibilities. The ATPase activity in purified plasma
membranes from glucose-starved or glucose-fermenting cells was
not stimulated in the presence of calmodulin, not even in
membranes obtained in the presence of EGTA to eliminate the
Ca#+-dependent membrane-bound calmodulin pool (results not
shown). This would suggest that either calmodulin is not a direct
ATPase activator or cytosolic factors required for in io
activation are lost during isolation of plasma membranes. Lack
of activation could also be explained by the existence of significant
amounts of calmodulin tightly bound to the plasma-membrane
fraction not solubilized during plasma-membrane isolation.
Complete solubilization of endogenous calmodulin would require
drastic treatments [35] which would abolish H+-ATPase activity.
When purified plasma membranes from glucose-starved or
glucose-fermenting cells were preincubated with calmidazolium,
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Figure 1 Concentration-dependence of in vitro H+-ATPase inhibition by
calmidazolium
ATPase activity was measured in the presence of several concentrations of calmidazolium, as
described in the Materials and methods section, using 10 (E), 20 (D) and 40 (_) lg/ml
purified plasma membranes from glucose-fermenting cells. The ATPase activity of membranes
not preincubated with the inhibitor, taken as 100%, was 1±87³0±07 lmol/min per mg. Results
are the means from three experiments. Inset, dependence of IC50 on plasma-membrane
concentration.
inhibition of the H+-ATPase activity was observed. In Figure 1,
the concentration-dependence of the inhibition caused by the
calmodulin antagonist is shown at several plasma-membrane
concentrations. The IC
&!
value for calmidazolium was different
depending on the plasma-membrane concentration and varied
from 1±1 to 3±0 lM at the protein concentrations assayed (Figure
1, inset).
Specificity of the inhibition of H+-ATPase activity by
calmidazolium
Membrane-dependence suggested that much of the added in-
hibitor was binding to the membranes. Since calmodulin
Figure 2 Effect of calmodulin on the in vitro inhibition of ATPase activity by calmidazolium and melittin
ATPase activities were measured in purified plasma membranes from glucose-fermenting cells, as described in the Materials and methods section, at a protein concentration of 20 lg/ml. The
membranes were preincubated with various concentrations of calmidazolium or melittin in the presence (D) or absence (E) of calmodulin (CaM). The ATPase activity of membranes not preincubated
with calmodulin antagonists, taken as 100%, was 2±32³0±1 lmol/min per mg. The results are means from three experiments.
antagonists can be considered to be cationic amphiphiles at
physiological pH, interaction with the lipid portion of the
membrane may take place. In fact, phospholipid-mediated effects
caused by calmidazolium have been previously reported, based
on 1:1 stoichiometric binding of inhibitor to phospholipid [36].
To dismiss this possibility, we estimated the stoichiometry of
calmidazolium binding. Approximate values of the inhibition
constant (K
i
) and binding stoichiometry for calmidazolium can
be obtained by a plot of IC
&!
against plasma-membrane con-
centration, where K
i
is the y intercept and 0±5 B the slope, where
B is the binding stoichiometry in nmol}mg of protein [36]. A K
i
of 0±4 lM and B of 150 nmol}mg were calculated from the data
of Figure 1 (inset). The inhibitor does not appear to bind to
membrane phospholipids with a 1:1 stoichiometry, since the
calculated amount of calmidazolium bound is lower than the
phospholipid content of the yeast plasma membrane [37]. Never-
theless, because of the dependence of the inhibition on plasma-
membrane concentration, equal amounts of membranes were
used in all experiments.
To assess the specificity of the inhibition ofH+-ATPase activity,
the effect of calmidazolium was compared with that of other
calmodulin antagonists. Melittin is a high-affinity calmodulin-
binding peptide [38] which inhibits calmodulin through a mech-
anism different from that of calmidazolium [39,40]. In Figure 2,
the concentration-dependence of the inhibition caused by both
calmodulin antagonists is shown. The IC
&!
values for
calmidazolium and melittin, 1±4 lM and 1±1 lM respectively,
were increased to 7±6 lM and 6±7 lM respectively in the presence
of calmodulin. Calmidazolium- and melittin-caused inhibition of
H+-ATPase activity occurs in purified plasma membranes from
both glucose-starved and glucose-fermenting cells not only from
wild-type, but also from pma1-P890X cells (results not shown).
The P890X mutation generates a C-terminus deletion that
produces an enzyme that is permanently in the activated state,
independent of glucose fermentation [13,16].
Binding of calmodulin to plasma-membrane proteins
The above results do not reveal the calmodulin target for
stimulation of H+-ATPase activity. It could be either a membrane
component tightly coupled to the H+-ATPase or the enzyme
itself. The calmodulin-binding domains of the target-binding
proteins show extreme sequence variability, although they share
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Figure 3 Detection of calmodulin-binding proteins in the plasma membrane
by 125I-calmodulin cross-linking
Aliquots of 80 lg of plasma membranes purified from glucose-treated cells were used in the
125I-calmodulin cross-linking reaction, which was performed in medium containing Ca2+ or
EGTA in the presence or absence of unlabelled calmodulin, as described in the Materials and
methods section. The autoradiograph of the proteins cross-linked to 125I-calmodulin, after
separation by SDS/PAGE, is shown in the first four lanes of the panel. The right line shows
a Western blot of a protein sample not treated with the cross-linking agent and probed with anti-
Pma1 monoclonal antibody. Molecular-mass standards are indicated in kDa on the left.
an amphiphilic structure [41]. Yeast H+-ATPase has no obvious
region with structural features of calmodulin-binding domains.
Nevertheless, we tested the possibility that the inhibitory effect of
the antagonists was mediated via elimination of calmodulin
binding to the ATPase. Figure 3 shows the pattern of calmodulin-
binding proteins of the plasma-membrane fraction from glucose-
fermenting cells obtained by "#&I-calmodulin cross-linking (simi-
lar results were obtained with membranes from glucose-starved
cells ; not shown). Calmodulin actually bound to several plasma-
membrane proteins in a Ca#+-dependent manner, and the binding
of labelled calmodulin to these proteins was completely blocked
by unlabelled calmodulin. However, no 116 kDa band cor-
responding to the calmodulin–ATPase complex was detected,
indicating that the target for calmodulin binding is not the
ATPase, but may rather be a membrane component.
DISCUSSION
The results presented here indicate that plasma-membrane H+-
ATPase activity is greatly reduced by calmodulin antagonists.
The inhibitors diminish the V
max
of H+-ATPase-catalysed ATP
hydrolysis, although the apparent affinity for MgATP is not
appreciably modified. Previous experiments using calmidazolium
assigned a role in glucose-induced activation of H+-ATPase to
one or more calmodulin-dependent kinases [18]. Our results
show that the calmodulin antagonists affect the basal activity of
the enzyme and that their inhibition is unrelated to activation by
glucose, as shown by the response to the antagonists of several
ATPase mutants affected in their glucose regulation. Thr-912 is
the phosphorylatable residue located in the potential phos-
phorylation site for calmodulin-dependent protein kinase II,
which is presumably involved in glucose regulation of the
ATPase. A mutant lacking this residue should therefore not be
affected by calmodulin antagonists. However, the V
max
of this
mutant ATPase was reduced on calmidazolium treatment. In-
hibition of mutant pma1-T912A together with the inhibition of a
mutant whose ATPase is completely independent of glucose
metabolism, pma1-P536L, demonstrate that a role in the ac-
tivation of H+-ATPase by glucose cannot be assigned to a
calmodulin-dependent protein kinase. Furthermore, inhibition
of ATPase activity in purified plasma membranes excludes an
effect of calmodulin antagonists via a calmodulin-dependent
protein kinase and suggests that a membrane component is
necessary for H+-ATPase activity as the calmodulin target. A
role for a calmodulin-dependent protein kinase in glucose
activation of the enzyme cannot be definitely ruled out, as it
could be masked by the inhibition of the V
max
caused by these
antagonists.
Many calmodulin inhibitors described are more or less non-
specific, in the sense that they are able to produce direct effects
on calmodulin effector enzymes as well as phospholipid-mediated
effects when used at high concentrations (50–75 lM) [35,42]. The
possibility that the action observed of calmodulin antagonists on
H+-ATPase is non-specific seems unlikely, since this inhibition is
produced in a concentration range that inhibits calmodulin-
mediated reactions in other systems (IC
&!
from 1 to 3 lM)
[43,44].Moreover, that this effect could bemediated by antagonist
interaction with calmodulin is indicated by the displacement of
the IC
&!
values in the presence of calmodulin. Further evidence
for the specificity of the calmodulin antagonists was obtained
from the similar response produced when calmodulin antagonists
with different modes of action were tested. Calmodulin
antagonists exert their inhibitory action on calmodulin-depen-
dent reactions by binding to the calmodulin molecule.
Calmidazolium binds to calmodulin predominantly via hydro-
phobic interactions [39], whereas not only hydrophobic but also
electrostatic interaction contributes to melittin–calmodulin bind-
ing [40].
Phospholipid-mediated effects by calmodulin antagonists have
been previously reported, based on a 1:1 stoichiometric binding
of inhibitor to phospholipid [36]. That this does not seem to be
the case here is indicated by the fact that the phospholipid
content of the yeast plasma membrane is higher than the apparent
binding stoichiometry found for calmidazolium [37]. However,
the dependence of the inhibition on membrane concentration
indicates a large amount of bound calmidazolium. This could
reflect the existence in the plasma membrane of several
calmodulin-specific receptor systems (Figure 3) or even the
interaction of part of the added inhibitor with the phospholipid
portion of the plasma membrane. Therefore the results are
compatible with the possibility that, of the large number of
calmidazolium molecules that bind, only a small number is
responsible for the specific inhibition of H+-ATPase activity.
Calmodulin regulates the activity of mammalian Ca#+-ATPase
by interaction with the C-terminal domain [45]. The "#&I-
calmodulin-binding protein pattern in the plasma-membrane
fraction eliminates H+-ATPase as the calmodulin effector en-
zyme, and points to a membrane component being indispensable
for its activity. Many membrane proteins exist as part of homo-
oligomeric or hetero-oligomeric structures. In fact, there is a
115 kDa glycoprotein that remains tightly associated with H+-
ATPase during purification of the enzyme [46], although it is not
essential for its activity [27]. It has recently been shown that two
small proteolipids are at least partially associated with H+-
ATPase in the plasma membrane [47]. A regulatory function for
these proteolipids has been proposed, since a strain lacking both
exhibited a lower V
max
for plasma-membrane H+-ATPase activity
and a wild-type K
m
for MgATP. Both proteolipids are predicted
to be amphipathic proteins [47,48] with a very basic hydrophilic
C-terminal domain, which shows, in the a-helical wheel rep-
resentation, the characteristic structural features of calmodulin-
binding domains [49]. It is tempting to speculate that the
calmodulin antagonists reduce the V
max
of H+-ATPase by acting
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on these proteolipids in a calmodulin-mediated effect.
Calmodulin-mediated regulation could represent an additional
regulatory mechanism of this essential enzyme in yeast, the
activity of which is under strict genetic and environmental
control.
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